MRI Delta Radiomics to Track Early Changes in Tumor Following Radiation: Application in Glioblastoma Mouse Model

Résumé fourni par la source

Background/Objectives: Glioblastoma (GBM) is an aggressive and lethal primary brain tumor with a poor prognosis, with a 5-year survival rate of approximately 5%. Despite advances in oncologic treatments, including surgery, radiotherapy, and chemotherapy, survival outcomes have remained stagnant, largely due to the failure of conventional therapies to address the tumor’s inherent heterogeneity. Radiomics, a rapidly emerging field, provides an opportunity to extract features from MRI scans, offering new insights into tumor biology and treatment response. This study evaluates the potential of delta radiomics, the study of changes in radiomic features over time in response to treatment or disease progression, exploring the potential of delta radiomics to track temporal radiation changes in tumor morphology and microstructure. Methods: A cohort of 50 female CD1 nude mice was injected intracranially with G7 glioblastoma cells and divided into irradiated (IR) and non-irradiated (non-IR) groups. MRI scans were performed at baseline (week 11) and post-radiation (weeks 12 and 14), and radiomic features, including shape, histogram, and texture parameters, were extracted and analyzed to capture radiation-induced changes. The most robust features were those identified through intra-observer reproducibility assessment, ensuring reliability in feature selection. A machine learning model was developed to classify irradiated tumors based on delta radiomic features, and statistical analyses were conducted to evaluate feature feasibility, stability, and predictive performance. Results: Our findings demonstrate that delta radiomics effectively captured significant temporal variations in tumor characteristics. Delta radiomics features exhibited distinct patterns across different time points in the IR group, enabling machine learning models to achieve a high accuracy. Conclusions: Delta radiomics offers a robust, non-invasive method for monitoring the treatment of glioblastoma (GBM) following radiation therapy. Future research should prioritize the application of MRI delta radiomics to effectively capture short-term changes resulting from intratumoral radiation effects. This advancement has the potential to significantly enhance treatment monitoring and facilitate the development of personalized therapeutic strategies.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.